Tumor Diagnosis

PMZ-1620 transiently alters the image of malignant but not benign solid tumors.

PMZ-1620 can be used to differentiate between a benign and a malignant tumor. In patients with breast cancer intravenous administration of PMZ-1620 shows a specific increase in tumor vessel diameter compared to baseline along with a corresponding decrease in resistive index. Patents granted in United States Patents No. 8,980,222, European Union (EP 05824775.0) and India (IP 243532).

Clinical stage – Phase III completed.

Status of Tumor Diagnosis


phase 1

phase 2

phase 3


Tumor Diagnosis (PMZ-1620)



  • Gulati, A., Sunila, E. S., and Kuttan, G. (2012) IRL-1620, an endothelin-B receptor agonist, enhanced radiation induced reduction in tumor volume in Dalton's Lymphoma Ascites tumor model. Arzneimittelforschung 62, 14-17
    Read more
  • Rajeshkumar, N. V., Matwyshyn, G., and Gulati, A. (2007) IRL-1620, a tumor selective vasodilator, augments the uptake and efficacy of chemotherapeutic agents in prostate tumor rats. Prostate 67, 701-713
    Read more
  • Rai, A., Rajeshkumar, N. V., and Gulati, A. (2006) Effect of the ET(B) receptor agonist, IRL-1620, on paclitaxel plasma pharmacokinetics of breast tumor rats. Exp Biol Med (Maywood) 231, 1120-1122
    Read more
  • Rajeshkumar, N. V., Rai, A., and Gulati, A. (2005) Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats. Breast Cancer Res Treat 94, 237-247
    Read more
  • Rai, A., Rajeshkumar, N. V., Shord, S., and Gulati, A. (2005) ET(B) receptor agonist, IRL 1620, does not affect paclitaxel plasma pharmacokinetics in breast tumour bearing rats. J Pharm Pharmacol 57, 869-876
    Read more
  • Rai, A., and Gulati, A. (2003) Evidence for the involvement of ET(B) receptors in ET-1-induced changes in blood flow to the rat breast tumor. Cancer Chemother Pharmacol 51, 21-28
    Read more